# VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

> **NCT04702425** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma (NHL)
- Acute Myeloid Leukemia (AML)
- Multiple Myeloma (MM)

## Interventions

- **DRUG:** VOB560
- **DRUG:** MIK665

## Key facts

- **NCT ID:** NCT04702425
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-23
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-07-23
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702425, "VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04702425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*